| Israel | Turki | Austria | |
| PET/CT tetap digunakan sebagai istilah dalam konteks medis di Indonesia | dari $1,300 | dari $650 | dari $1,450 |
Bookimed tidak menambah biaya tambahan dalam harga PET/CT tetap digunakan sebagai istilah dalam konteks medis di Indonesia. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik untuk PET/CT tetap digunakan sebagai istilah dalam konteks medis di Indonesia Anda saat tiba.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam PET/CT tetap digunakan sebagai istilah dalam konteks medis di Indonesia dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan PET/CT tetap digunakan sebagai istilah dalam konteks medis di Indonesia Anda.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.
He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.
Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.
Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).
His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.
He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.
He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.